|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.03 USD | -3.51% |
|
+6.84% | +31.71% |
| 07-24 | Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating | MT |
| 07-23 | NovoCure Limited, Q2 2026 Earnings Call, Jul 23, 2026 |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Bullish |
| Resistance | 19.99 | 19.99 | 17.96 |
| Spread/Res. | -14.81% | -14.81% | -5.18% |
| Spread/Supp. | +3.71% | +25.13% | +24.58% |
| Support | 16.42 | 13.61 | 13.67 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- NVCR Stock
- Charts NovoCure Limited
Select your edition
All financial news and data tailored to specific country editions
